Selecting Nanobodies Specific for the Epidermal Growth Factor from a Synthetic Nanobody Library
Yunier Serrano-Rivero1, Julieta Salazar-Uribe1, Marcela Rubio-Carrasquilla1
1Faculty of Basic Sciences, University of Medellin, Medellin 050026, Colombia.
Abstract:
The epidermal growth factor (EGF) is one of the most critical ligands of the EGF receptor (EGFR), a well-known oncogene frequently overexpressed in cancerous cells and an important therapeutic target in cancer. The EGF is the target of a therapeutic vaccine aimed at inducing an anti-EGF antibody response to sequester this molecule from serum. However, strikingly, very few investigations have focused on EGF immunotargeting. Since the use of nanobodies (Nbs) for EGF neutralization may be an effective therapeutic strategy in several types of cancer, in this study, we decided to generate anti-EGF Nbs from a recently constructed, phage-displaying synthetic nanobody library. To our knowledge, this is the first attempt to obtain anti-EGF Nbs from a synthetic library. By applying a selection strategy that uses four different sequential elution steps along with three rounds of selection, we obtained four different EGF-specific Nb clones, and also tested their binding capabilities as recombinant proteins. The obtained results are very encouraging and demonstrate the feasibility of selecting nanobodies against small antigens, such as the EGF, from synthetic libraries.
Insights
Researchers generated novel nanobodies targeting epidermal growth factor (EGF) using a synthetic library. This study demonstrates the feasibility of using nanobodies for cancer therapy by neutralizing EGF.
Area of Science:
- Biotechnology
- Immunology
- Oncology
Background:
- Epidermal growth factor (EGF) is a critical ligand for the EGF receptor (EGFR), an oncogene often overexpressed in cancers.
- Targeting EGF is a therapeutic strategy to neutralize its role in cancer progression.
- Few studies have explored immunotargeting of EGF.
Purpose of the Study:
- To generate anti-EGF nanobodies (Nbs) from a synthetic phage display library.
- To evaluate the potential of these Nbs as a therapeutic strategy for cancer treatment.
- To demonstrate the feasibility of selecting nanobodies against small antigens from synthetic libraries.
Main Methods:
- Construction of a synthetic nanobody library displayed on phage.
- Selection of EGF-specific nanobodies using a multi-step elution strategy.
- Production and testing of binding capabilities of recombinant anti-EGF nanobody clones.
Main Results:
- Successfully obtained four distinct EGF-specific nanobody clones.
- Confirmed the binding capabilities of the selected nanobodies as recombinant proteins.
- Demonstrated the feasibility of generating nanobodies against small antigens like EGF from synthetic libraries.
Conclusions:
- The generation of anti-EGF nanobodies from a synthetic library is feasible.
- These nanobodies show promise for therapeutic applications in EGF-related cancers.
- This approach opens new avenues for developing targeted cancer immunotherapies.
More Related Videos
08:09Validation of Nanobody and Antibody Based In Vivo Tumor Xenograft NIRF-imaging Experiments in Mice Using Ex Vivo Flow Cytometry and Microscopy
Published on: April 6, 2015
07:32Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library
Published on: September 30, 2019